checkAd

Novo Nordisk Opportunities Are Under-Appreciated, BofA Says, Reiterating Buy

(PLX AI) – Novo Nordisk has key opportunities in addition to weight-loss drug Wegovy, which are currently under-appreciated by the market, analysts at Bank of America said, reiterating a buy recommendation on the stock.Multiple Novo Nordisk assets …

  • (PLX AI) – Novo Nordisk has key opportunities in addition to weight-loss drug Wegovy, which are currently under-appreciated by the market, analysts at Bank of America said, reiterating a buy recommendation on the stock.
  • Multiple Novo Nordisk assets due to report phase 3 data are under the radar, with focus likely to increase into March investor day, BofA said
  • Among them are icodec, a novel basal insulin, and semaglutide/cagrilintide
  • The key to the Novo thesis in the short term remains the Wegovy launch with the delay in increased supply, with a possible risk the new guidance for 2022, BofA said
  • The analysts maintained a price target of DKK 780 for Novo Nordisk


Der Analyst erwartet ein Kursziel von 104,94, was eine Steigerung von +inf% zum aktuellen Kurs entspricht. Mit diesen Produkten können Sie die Kurserwartungen des Analysten übertreffen.
Übernehmen
Für Ihre Einstellungen haben wir keine weiteren passenden Produkte gefunden.
Bitte verändern Sie Kursziel, Zeitraum oder Emittent.
Alternativ können Sie auch unsere Derivate-Suchen verwenden
Knock-Out-Suche | Optionsschein-Suche | Zertifikate-Suche
WerbungDisclaimer
Wertpapier



0 Kommentare
Autor: PLX AI
 |  169   |   |   

Schreibe Deinen Kommentar

Disclaimer

Novo Nordisk Opportunities Are Under-Appreciated, BofA Says, Reiterating Buy (PLX AI) – Novo Nordisk has key opportunities in addition to weight-loss drug Wegovy, which are currently under-appreciated by the market, analysts at Bank of America said, reiterating a buy recommendation on the stock.Multiple Novo Nordisk assets …

Nachrichten des Autors

Titel
Titel
Titel
Titel